Analysts have been eager to weigh in on the Healthcare sector with new ratings on Crinetics Pharmaceuticals (CRNX – Research Report), Exelixis (EXEL – Research Report) and Fusion Pharmaceuticals (FUSN – Research Report).
Crinetics Pharmaceuticals (CRNX)
Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Crinetics Pharmaceuticals on January 25 and set a price target of $50.00. The company’s shares closed last Monday at $37.70, close to its 52-week high of $38.98.
According to TipRanks.com, Schwartz is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Crinetics Pharmaceuticals with a $48.00 average price target, representing a 29.3% upside. In a report issued on January 16, Morgan Stanley also initiated coverage with a Buy rating on the stock with a $50.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Exelixis (EXEL)
Leerink Partners analyst Christopher Liu maintained a Hold rating on Exelixis on January 26 and set a price target of $19.00. The company’s shares closed last Monday at $21.89.
According to TipRanks.com, Liu is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Exelixis with a $26.44 average price target.
Fusion Pharmaceuticals (FUSN)
Leerink Partners analyst Faisal Khurshid reiterated a Buy rating on Fusion Pharmaceuticals yesterday and set a price target of $17.00. The company’s shares closed last Monday at $11.50.
Khurshid has an average return of
According to TipRanks.com, Khurshid is ranked #315 out of 8693 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Fusion Pharmaceuticals with a $14.33 average price target, a 29.2% upside from current levels. In a report issued on January 25, JonesTrading also maintained a Buy rating on the stock with a $12.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CRNX:
- 3 Best Stocks to Buy Now, 1/17/2024, According to Top Analysts
- Crinetics initiated with an Overweight at Morgan Stanley
- Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- The biotech stocks to own in 2024, according to Piper Sandler
- Biotech Alert: Searches spiking for these stocks today
